Pembrolizumab-trastuzumab-chemo a new treatment alternative for gastric cancer?
01 Sep 2021
byAudrey Abella
In a prespecified interim analysis of the phase III KEYNOTE-811 study presented at ESMO GI 2021, the addition of pembrolizumab to standard of care (SoC) first-line therapy comprising trastuzumab and chemotherapy led to a significant improvement in overall response rate (ORR) in previously untreated individuals with HER2-positive, metastatic gastric or gastroesophageal junction (G/GEJ) cancer.
